Literature DB >> 1195129

Effects of route of administration and blood flow on hepatic drug elimination.

D G Shand, D M Kornhauser, G R Wilkinson.   

Abstract

The effects of route of administration and blood flow on the elimination of lidocaine, diphenylhydantoin and propranolol have been investigated in the isolated perfused rat liver. After administration directly into the portal vein, drug concentrations in the reservoir were the same at a given flow rate as concentrations in the hepatic vein after drug was placed directly into the reservoir. The apparent clearance of the drug calculated from these concentrations gave an estimate of intrinsic drug clearance, which is an estimate of the activity of the drug-metabolizing enzymes. Intrinsic clearance is defined as drug clearance when flow is not rate limiting and therefore should be independent of flow. This was confirmed by showing that, at steady state, neither hepatic venous drug concentrations nor concentrations in the reservoir after portal venous administration of lidocaine were affected by altering hepatic blood flow from 10 to 20 ml/min. Propranolol was given as a single dose into the reservoir at flows of 10 and 20 ml/min. The area under the concentration-time curve (AUC) in the reservoir was decreased by increased flow, but AUC for hepatic venous blood was unchanged. Although AUC in hepatic venous blood was unchanged. Although AUC in hepatic venous blood was unchanged, higher peak concentrations and a more rapid half-life was seen in keeping with the clearance of drug from the reservoir. These data suggest that after oral drug administration, steady-state concentrations or AUC in systemic blood is dependent only on the activity of the enzymes involved (i.e., intrinsic clearance) and unaffected by flow, provided drug is completely absorbed and eliminated only by the liver. Furthermore, this will apply even to drugs whose systemic clearance and drug half-life after i.v. administration is profoundly affected by altered hepatic blood flow.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1195129

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  31 in total

Review 1.  Altered hepatic blood flow and drug disposition.

Authors:  A S Nies; D G Shand; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

2.  A comparative investigation of hepatic clearance models: predictions of metabolite formation and elimination.

Authors:  M V St-Pierre; P I Lee; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1992-04

3.  Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugs.

Authors:  L P Rivory; M S Roberts; S M Pond
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

4.  Effect of exercise on propranolol pharmacokinetics.

Authors:  S Frank; S M Somani; M Kohnle
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Absolute bioavailability of imipramine: influence of food.

Authors:  D R Abernethyl; M Divoll; D J Greenblatt; J S Harmatz; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 6.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 7.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

8.  Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.

Authors:  H I Pirttiaho; E A Sotaniemi; R O Pelkonen; U Pitkänen; M Anttila; H Sundqvist
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

Review 10.  Propranolol disposition in chronic liver disease: a physiological approach.

Authors:  R A Branch; D G Shand
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.